<SEC-DOCUMENT>0001193125-17-259688.txt : 20170816
<SEC-HEADER>0001193125-17-259688.hdr.sgml : 20170816
<ACCEPTANCE-DATETIME>20170816151108
ACCESSION NUMBER:		0001193125-17-259688
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20170815
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170816
DATE AS OF CHANGE:		20170816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		171036138

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d440461d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;15, 2017 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2017, FibroGen, Inc. (the &#147;Registrant&#148;) entered into an underwriting agreement with Goldman Sachs&nbsp;&amp; Co. LLC, Citigroup
Global Markets Inc. and Leerink Partners LLC (collectively, the &#147;Underwriters&#148;), relating to the issuance and sale of 8,000,000 shares of the Registrant&#146;s common stock (the &#147;Offering&#148;) at a price to the public of $40.75 per
share. The gross proceeds to the Registrant from the Offering are expected to be $326&nbsp;million before deducting the underwriting discounts and commissions and offering expenses payable by the Registrant. The offering is scheduled to close on or
about August&nbsp;21, 2017, subject to customary closing conditions. In addition, under the terms of the underwriting agreement, the Registrant has granted the Underwriters an option, exercisable for 30 days from the date of the underwriting
agreement, to purchase up to an additional 1,200,000 shares of the Registrant&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement contains customary
representations, warranties, covenants and agreements by the Registrant, indemnification obligations of the Registrant and the underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and
termination provisions. The representations, warranties and covenants contained in the underwriting agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the underwriting
agreement, and may be subject to limitations agreed upon by the contracting parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made by means of a written prospectus
supplement and accompanying prospectus forming part of a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-216368),</FONT> previously filed with the
Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement is attached as Exhibit 1.1 hereto, and the description of the terms of the underwriting
agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the Offering is attached as Exhibit 5.1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2017, the Registrant issued a press release announcing the pricing of the Offering. A copy of this press release is attached as Exhibit
99.1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the disclosures on this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> nor the attached press release shall
constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement by and among Goldman Sachs&nbsp;&amp; Co. LLC, Citigroup Global Markets Inc., Leerink Partners LLC and the Registrant, dated August&nbsp;15, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;FibroGen, Inc. Announces Pricing of <FONT STYLE="white-space:nowrap">Follow-on</FONT> Offering of Common Stock,&#148; dated August&nbsp;15, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FibroGen, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Pat Cotroneo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pat Cotroneo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;15, 2017</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d440461dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 1.1</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen,
Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock, par value $0.01 per share </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Underwriting Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;15,<B> </B>2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs&nbsp;&amp; Co. LLC, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives (the
&#147;Representatives&#148;) of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">named in Schedule I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets
Inc., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Federal St, 37F, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., a Delaware corporation (the &#147;Company&#148;), proposes, subject to the terms and conditions stated in this Agreement (this
&#147;Agreement&#148;), to issue and sell to the Underwriters named in Schedule I hereto (the &#147;Underwriters&#148;) an aggregate of 8,000,000 shares (the &#147;Firm Shares&#148;) and, at the election of the Underwriters, up to 1,200,000
additional shares (the &#147;Optional Shares&#148;), of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section&nbsp;2 hereof
being collectively called the &#147;Shares&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company represents and warrants to, and agrees with, each of the Underwriters
that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) An &#147;automatic shelf registration statement&#148; as defined under Rule 405 under the Securities Act of
1933, as amended (the &#147;Act&#148;), on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-216368)</FONT> in respect of the Shares has been filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) not earlier than three years prior to the date hereof; such registration statement, and any post-effective amendment thereto, became effective on filing; and no stop order suspending the effectiveness of such registration
statement or any part thereof has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
issued and no proceeding for that purpose has been initiated or, to the Company&#146;s knowledge, threatened by the Commission, and no notice of objection of the Commission to the use of such
registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act has been received by the Company (the base prospectus filed as part of such registration statement, in the form in which it has most recently
been filed with the Commission on or prior to the date of this Agreement is hereinafter called the &#147;Basic Prospectus&#148;; any preliminary prospectus (including any preliminary prospectus supplement) relating to the Shares filed with the
Commission pursuant to Rule 424(b) of the rules and regulations of the Commission under the Act, is hereinafter called a &#147;Preliminary Prospectus&#148;; the various parts of such registration statement, including all exhibits thereto and
including any prospectus supplement relating to the Shares that is filed with the Commission and deemed by virtue of Rule 430B to be part of such registration statement, each as amended at the time such part of the registration statement became
effective, are hereinafter collectively called the &#147;Registration Statement&#148;; the Basic Prospectus, as amended and supplemented immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof), is hereinafter called the
&#147;Pricing Prospectus&#148;; the form of the final prospectus relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof is hereinafter called the &#147;Prospectus&#148;; any
reference herein to the Basic Prospectus, the Pricing Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Act, as of the date of such prospectus; any reference to any amendment or supplement to the Basic Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any
post-effective amendment to the Registration Statement, any prospectus supplement relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Act and any documents filed under the Securities Exchange Act of 1934, as amended
(the &#147;Exchange Act&#148;), and incorporated therein, in each case after the date of the Basic Prospectus, such Preliminary Prospectus, or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall be
deemed to refer to and include any annual report of the Company filed pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement;
and any &#147;issuer free writing prospectus&#148; as defined in Rule 433 under the Act relating to the Shares is hereinafter called an &#147;Issuer Free Writing Prospectus&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (A) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been
issued by the Commission, and (B)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder, and did not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided, however,
</I>that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section&nbsp;9(b) of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Agreement, the &#147;Applicable Time&#148; is 6:15 p.m. (Eastern time) on the date of this
Agreement. The Pricing Prospectus, as of the Applicable Time, as supplemented by each Issuer Free Writing Prospectus listed on Schedule II(a) hereto, when taken together with the price to the public and the number of Securities to be set forth on
the cover of the Prospectus (collectively, the &#147;Pricing Disclosure Package&#148;), as of the Applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Time, did not, and as of each Time of Delivery (as defined in Section&nbsp;4(a) of this Agreement) will not, include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus listed on Schedule II(a) hereto does not conflict with the information contained
in the Registration Statement, the Pricing Prospectus or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the Pricing Disclosure Package as of the Applicable Time, did not include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty
shall not apply to statements or omissions made in an Issuer Free Writing Prospectus in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The documents incorporated by reference in the Pricing Prospectus and the Prospectus, when they became effective or were
filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder, and to the Company&#146;s knowledge,
none of such documents, when they became effective or were filed with the Commission, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not
misleading; any further documents so filed and incorporated by reference in the Prospectus or any further amendment or supplement thereto, when such documents become effective or are filed with the Commission, as the case may be, will conform in all
material respects to the applicable requirements of the Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein, in light of the circumstance in which they were made, or necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions
made in reliance upon and in conformity with the Underwriter Information; and no such documents were filed with the Commission since the Commission&#146;s close of business on the business day immediately prior to the date of this Agreement and
prior to the execution of this Agreement, except as set forth on Schedule II(b) hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i) The Registration Statement
conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder
and (ii)&nbsp;the Registration Statement and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus do not and will not, as of the applicable effective date as to each part of the Registration
Statement and any amendment thereto and as of the applicable filing date and such Time of Delivery (as defined below) as to the Prospectus and any amendment or supplement thereto, contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity
with the Underwriter Information; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its subsidiaries has sustained since the date
of the latest audited financial statements included or incorporated by reference in the Pricing Prospectus any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the
Pricing Prospectus, there has not been any change in the capital stock (other than as a result of (A)&nbsp;the exercise of any stock options outstanding as of the date of this Agreement or warrants outstanding as of the date of this Agreement,
(B)&nbsp;the award of stock options in the ordinary course of business pursuant to the Company&#146;s equity incentive plans or (C)&nbsp;the repurchase of shares of Stock in connection with any early exercise of stock options by option holders from
employees terminating their service to the Company, in each case as such options, warrants and equity incentive plans are described in the Pricing Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its
subsidiaries or any material adverse change, or any development involving a prospective material adverse change, in or affecting the general affairs, management, financial position, stockholders&#146; equity or results of operations of the Company
and its subsidiaries, otherwise than as set forth or contemplated in the Pricing Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company and its
subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described in
the Pricing Prospectus or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under
lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases (subject to the effects of (A)&nbsp;bankruptcy, insolvency, fraudulent conveyance, fraudulent transfer, reorganization, moratorium or other
similar laws relating to or affecting the rights or remedies of creditors generally; (B)&nbsp;the application of general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing,
regardless of whether enforcement is considered in proceedings at law or in equity); and (C)&nbsp;applicable law and public policy with respect to rights to indemnity and contribution) with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, taken as a whole; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
State of Delaware, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Prospectus and the Prospectus, and has been duly qualified as a foreign corporation for the transaction of
business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, or is subject to no material liability or disability by reason of the
failure to be so qualified or be in good standing in any such jurisdiction; and each subsidiary of the Company has been duly incorporated or formed and is validly existing as a corporation or other business organization in good standing under the
laws of its jurisdiction of incorporation or formation, and has been duly qualified as a foreign corporation or other business organization for the transaction of business and is in good standing under the laws of each other jurisdiction in which it
owns or leases properties or conducts any business so as to require such qualification, or is subject to no material liability or disability by reason of the failure to be so qualified or be in good standing in any such jurisdiction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company has an authorized capitalization as set forth in the Pricing
Prospectus and the Prospectus and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform to the description
of the Stock contained in the Pricing Disclosure Package and the Prospectus; and all of the issued shares of capital stock and equity interests of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and (except for directors&#146; qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Shares have been duly and validly authorized and, when issued and delivered against payment therefor as provided
herein, will be duly and validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The issue and sale of the Shares and the compliance by the Company with this Agreement and the consummation of the
transactions herein contemplated (i)&nbsp;will not materially conflict with or result in a material breach or violation of any of the terms or provisions of, or constitute a material default under, any indenture, mortgage, deed of trust, loan
agreement, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its
subsidiaries is subject, (ii)&nbsp;will not conflict with or result in a breach or violation of any of the terms or provisions of the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company or the
corresponding governing documents of any of its subsidiaries and (iii)&nbsp;will not conflict with or result in a breach or violation of any of the terms or provisions of any statute or any order, rule or regulation of any court or governmental
agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is
required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except for the registration under the Act of the Shares, the approval by the Financial Industry Regulatory Authority
(&#147;FINRA&#148;) of the underwriting terms and arrangements and such consents, approvals, authorizations, orders, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and
distribution of the Shares by the Underwriters; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its subsidiaries is (i)&nbsp;in
violation of its Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, (ii)&nbsp;in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound or (iii)&nbsp;in violation or default of any statute, law, rule, regulation, judgment, order
or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company, its subsidiaries or any of their properties, as applicable; except in the case of (iii), for such
defaults as would not, individually or in the aggregate, have a Material Adverse Effect (as defined below); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The
statements set forth in the Pricing Prospectus and the Prospectus under the caption &#147;Description of Capital Stock&#148;, insofar as they purport to constitute a summary of the terms of the Stock, and under the captions
&#147;Business&#151;Roxadustat for the Treatment of Anemia in Chronic Kidney Disease in China&#148;, &#147;Business&#151;Government Regulation&#148;, &#147;Business&#151;Intellectual Property&#148;, &#147;Risk Factors&#151; Risks Related to Our
Intellectual Property&#148;, &#147;Risk Factors&#151;Risks Related to Government Regulation&#148;, &#147;Certain Relationships and Related Party Transactions&#148; and &#147;Underwriting&#148;, insofar as they purport to describe the provisions of
the laws and documents referred to therein, are accurate, complete and fair in all material respects; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Other than as set forth in the Pricing Prospectus and the Prospectus, there
are no legal or governmental proceedings pending to which the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company is a party or of which any property or assets of the Company or any of its
subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company is the subject which, if determined adversely to the Company or any of its subsidiaries, would individually or in the aggregate have a material adverse effect
on the current or future financial position, stockholders&#146; equity or results of operations of the Company and its subsidiaries, taken as a whole (a &#147;Material Adverse Effect&#148;); and, to the best of the Company&#146;s knowledge, no such
proceedings are threatened or contemplated by governmental authorities or threatened by others; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company is not
and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Pricing Prospectus and the Prospectus, will not be an &#147;investment company&#148;, as such term is defined in the
Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <B></B>(A)&nbsp;(i) At the time
of filing the Registration Statement, (ii)&nbsp;at the time of the most recent amendment thereto for the purposes of complying with Section&nbsp;10(a)(3) of the Act (whether such amendment was by post-effective amendment, incorporated report filed
pursuant to Section&nbsp;13 or 15(d) of the Exchange Act or form of prospectus), and (iii)&nbsp;at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Act) made any offer
relating to the Shares in reliance on the exemption of Rule 163 under the Act, the Company was a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Act; and (B)&nbsp;at the earliest time after the filing of the Registration
Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, the Company was not an &#147;ineligible issuer&#148; as defined in Rule 405 under the Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) PricewaterhouseCoopers LLP, who have audited the financial statements of the Company and its subsidiaries, is an
independent registered public accounting firm as required by the Act and the rules and regulations of the Commission thereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) The Company maintains a system of internal control over financial reporting (as such term is defined in Rule <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act that complies with the requirements of the Exchange Act and has been designed by the Company&#146;s principal executive officer and principal financial officer, or under their
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company is not aware of
any material weaknesses in its internal control over financial reporting; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) Since the date of the latest audited
financial statements included or incorporated by reference in the Pricing Prospectus and the Prospectus, there has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely
to materially affect, the Company&#146;s internal control over financial reporting; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The Company maintains disclosure controls and procedures (as such term is
defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating
to the Company and its subsidiaries is made known to the Company&#146;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) None of the Company, any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee,
affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political
activity; (ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977;
(iv) violated or is in violation of any provision of the Bribery Act 2010 of the United Kingdom or (v)&nbsp;made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) (i) The Company and each of its subsidiaries owns, possesses, licenses or has other rights to practice and use all patents,
trademarks, service marks, trade names, domain names, copyrights and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and all other unpatented and/or unpatentable proprietary information, confidential information, systems
and processes) and all other technology and intellectual property rights practiced or used by it or necessary for the conduct of its respective business as currently conducted and as proposed to be conducted in the Registration Statement or the
Pricing Prospectus (collectively, the &#147;Intellectual Property&#148;), and, to the Company&#146;s knowledge, the conduct of its and its subsidiaries&#146; respective business (including the development and commercialization of the products
described in the Registration Statement or the Pricing Prospectus) has not and will not infringe, misappropriate or otherwise violate or conflict with any intellectual property rights of others; (ii)&nbsp;except as described in the Pricing
Prospectus, (A)&nbsp;neither the Company nor any of its subsidiaries have received any notice of any claim of infringement, misappropriation or other violation of or conflict with any such rights of others, (B)&nbsp;there are no third parties who
have or, to the Company&#146;s knowledge, will be able to establish ownership rights in or to any Intellectual Property owned or purported to be owned by the Company or any of its subsidiaries, or any right to practice or use any Intellectual
Property owned or purported to be owned by or exclusively licensed to the Company or any of its subsidiaries, (C)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the
Company&#146;s or any of its subsidiaries&#146; rights in or to any Intellectual Property, (D)&nbsp;the Intellectual Property owned or purported to be owned by or exclusively licensed to the Company or any of its subsidiaries is valid and
enforceable, and there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability or scope of any Intellectual Property owned or purported to be owned by or
exclusively licensed to the Company or any of its subsidiaries, (E)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes,
misappropriates or otherwise violates or conflicts with any intellectual property or other proprietary rights of others, and (F)&nbsp;there is no pending or threatened action, suit, proceeding or claim by the Company or any of its subsidiaries that
a third party infringes, misappropriates or otherwise violates or conflicts with any Intellectual Property; (iii)&nbsp;to the Company&#146;s knowledge, no Intellectual Property has been obtained or is being practiced or used by the Company or any of
its subsidiaries in violation of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
contractual obligation binding on the Company or any of its subsidiaries, or otherwise in violation of the rights of any persons, except, in the case of each of (i)&nbsp;through (iii) above, as
would not, individually or in the aggregate, be material in light of all relevant facts and circumstances to the Company and its subsidiaries, taken as a whole; (iv)&nbsp;there are no outstanding options, licenses or binding agreements of any kind
relating to the Intellectual Property owned or purported to be owned by or exclusively licensed to the Company or any of its subsidiaries that are required to be described in the Registration Statement or the Pricing Prospectus and are not so
described; (v)&nbsp;neither the Company nor any of its subsidiaries is a party to or bound by any options, licenses or binding agreements with respect to any intellectual property of any other person or entity that are required to be set forth in
the Registration Statement or the Pricing Prospectus and are not so described; (vi)&nbsp;to the Company&#146;s knowledge, no employee, consultant or independent contractor of the Company or any of its subsidiaries is in or has ever been in violation
in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
agreement nondisclosure agreement or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#146;s employment or independent contractor&#146;s engagement with the
Company or actions undertaken while employed or engaged with the Company; (vii)&nbsp;no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in
the development of any Intellectual Property that is owned or purported to be owned by or, to the knowledge of the Company, licensed to the Company or any of its subsidiaries, and no governmental agency or body, university, college, other
educational institution or research center has any claim or right in or to any Intellectual Property that is owned or purported to be owned by or, to the knowledge of the Company, exclusively licensed to the Company or any of its subsidiaries;
(viii)&nbsp;the Company and each of its subsidiaries has the right to sue for past, present and future infringement, misappropriation, violation and conflict with all Intellectual Property owned or purported to be owned by it without restriction;
and (ix)&nbsp;the Company and each of its subsidiaries has taken reasonable steps necessary to (A)&nbsp;secure its interests in the Intellectual Property (I)&nbsp;owned or purported to be owned by or exclusively licensed to it and
(II)&nbsp;developed by its employees, consultants, agents and contractors in the course of their service to the Company or such subsidiary and (B)&nbsp;maintain the confidentiality of all material know how (including trade secrets and all other
unpatented and/or unpatentable proprietary information, confidential information, systems and procedures) owned, used or held for use by it; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) (i) the ownership structure (the &#147;Ownership Structure&#148;) set forth in Annex II of this Agreement complies with all
applicable laws, rules and regulations, including those of the People&#146;s Republic of China (the &#147;PRC&#148;), Hong Kong, the Cayman Islands and the United States, does not violate, breach, contravene or otherwise conflict with any applicable
laws, rules and regulations and has not been challenged by any governmental agency; (ii)&nbsp;there are no legal, arbitral, governmental or other proceedings (including, without limitation, governmental investigations or inquiries) pending before or
threatened or contemplated by any governmental agency in respect of such Ownership Structure; (iii)&nbsp;all consents, approvals, authorizations, orders, registrations, clearances or qualifications of or with any governmental agency
(&#147;Governmental Authorizations&#148;) in connection with the Ownership Structure have been duly granted, made or unconditionally obtained in writing and are in full force and effect and no such Governmental Authorization has been withdrawn or
revoked or is subject to any condition precedent which has not been fulfilled or performed; (iv)&nbsp;after the consummation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the offering of Shares hereunder, the Ownership Structure will comply with all applicable laws, rules and regulations; (v)&nbsp;all of the Company&#146;s subsidiaries incorporated or formed in
the PRC and Hong Kong have taken all reasonable steps to comply with any applicable rules and regulations of the PRC State Administration of Foreign Exchange (the &#147;SAFE Rules and Regulations&#148;), including, without limitation, requesting
each shareholder and option holder that is, or is directly or indirectly owned or controlled by, a PRC resident or citizen to complete any registration and other procedures required under the SAFE Rules and Regulations; and (vi)&nbsp;(A) dividends
and other distributions declared with respect to <FONT STYLE="white-space:nowrap">after-tax</FONT> retained earnings on the share capital of any subsidiary of the Company that is or will be incorporated in the PRC will be permitted under the current
laws and regulations of the PRC to be freely transferred out of the PRC and may be paid in U.S. dollars, subject to the successful completion of PRC formalities required for such remittance, and all such dividends and other distributions will not be
subject to withholding or other taxes under the laws and regulations of the PRC and are otherwise free and clear of any other tax, withholding or deduction in the PRC, and without the necessity of obtaining any Governmental Authorizations;
(B)&nbsp;dividends and other distributions declared and payable on the share capital of any subsidiary of the Company that is or will be incorporated in Hong Kong will be permitted under the current laws and regulations of Hong Kong and the PRC to
be paid to the Company, and all such dividends and other distributions will not be subject to withholding or other taxes under the laws and regulations of Hong Kong and the PRC and are otherwise free and clear of any other tax, withholding or
deduction in Hong Kong and the PRC and without the necessity of obtaining any Governmental Authorizations of or with any governmental agency in Hong Kong or the PRC and (C)&nbsp;dividends and other distributions declared and payable on the share
capital of any subsidiary of the Company that is or will be incorporated in the Cayman Islands will be permitted under the current laws and regulations of the Cayman Islands to be paid to the Company, and all such dividends and other distributions
will not be subject to withholding or other taxes under the laws and regulations of the Cayman Islands and are otherwise free and clear of any other tax, withholding or deduction in the Cayman Islands and without the necessity of obtaining any
Governmental Authorizations of or with any governmental agency in the Cayman Islands; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) There are no persons with
registration rights or other similar rights to have any securities registered pursuant to the Registration Statement or otherwise registered by the Company under the Act except as have been validly waived or complied with; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions where the Company and its subsidiaries conduct business, including but
not limited to the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency having jurisdiction over the Company or any of its subsidiaries (collectively, the &#147;Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) (i) None of the Company, any of its subsidiaries or, to the knowledge of the
Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries (A)&nbsp;is currently the subject or the target of any sanctions administered or enforced by the United States government, including, without
limitation, the Office of Foreign Assets Control of the United States Department of the Treasury, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), (B) does any business with or involving the government of, or any person
or project located in, any country targeted by any Sanctions or (C)&nbsp;supports or facilitates any such business or project, in each case other than as permitted under such Sanctions; (ii)&nbsp;the Company is not controlled (within the meaning of
the executive orders or regulations promulgating Sanctions) by any government or person that is the subject or target of Sanctions; (iii)&nbsp;the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or
lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (A)&nbsp;to fund any activities of or business with any person, or in any country or territory, that, at the time of such
funding, is the subject of Sanctions or (B)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions and
(iv)&nbsp;the Company has implemented and maintains adequate internal controls and procedures to monitor and audit transactions that are reasonably designed to detect and prevent any use of the proceeds from the offering contemplated hereby that is
inconsistent with any of the Company&#146;s representations and obligations under clause (iii)&nbsp;of this paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company and its subsidiaries and their respective properties, assets and operations are in compliance with, and the
Company and each of its subsidiaries hold all permits, authorizations and approvals required under Environmental Laws (as defined below); there are no past, present or reasonably anticipated future events, conditions, circumstances, activities,
practices, actions, omissions or plans that could reasonably be expected to give rise to any material costs or liabilities to the Company or any of its subsidiaries under, or to interfere with or prevent compliance by the Company or any of its
subsidiaries with, Environmental Laws; none of the Company and its subsidiaries (i)&nbsp;is the subject of any investigation, (ii)&nbsp;has received any notice or claim, (iii)&nbsp;is a party to or affected by any pending or, to its knowledge,
threatened action, suit or proceeding, (iv)&nbsp;is bound by any judgment, decree or order or (v)&nbsp;has entered into any agreement, in each case relating to any alleged violation of any Environmental Law or any actual or alleged release or
threatened release or cleanup at any location of any Hazardous Materials (as defined below) (as used herein, &#147;Environmental Law&#148; means any national, provincial, municipal or other local or foreign law, statute, ordinance, rule, regulation,
order, notice, directive, decree, judgment, injunction, permit, license, authorization or other binding requirement, or common law, relating to health, safety or the protection, cleanup or restoration of the environment or natural resources,
including those relating to the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release or threatened release of Hazardous Materials, and &#147;Hazardous Materials&#148; means any material
(including, without limitation, pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise to liability under any Environmental Law); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) Any statistical, industry-related and market-related data included in the Pricing Prospectus and the Prospectus are based
on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) (i) The Company has operated and currently is in compliance in all respects
with all applicable rules and regulations of the United States Food and Drug Administration (the &#147;FDA&#148;) and other governmental agencies; (ii)&nbsp;the Company and its subsidiaries (A)&nbsp;possess, and are in compliance with the terms of,
all licenses, permits, approvals, certificates, registrations, franchises, clearances, exemptions and other authorizations necessary to conduct their respective businesses (collectively, &#147;Licenses&#148;), including, without limitation, all
Licenses required by the FDA and/or by any other governmental agencies, which Licenses are in full force and effect, (B)&nbsp;have not received any notice from any governmental agency relating to the revocation or modification of any Licenses that,
if determined adversely to the Company or its subsidiaries, would reasonably be expected to have a material impact on the Company and (C)&nbsp;are not aware of any other action by any governmental agency to limit, suspend, terminate or revoke any
License held by the Company or any of its subsidiaries; (iii)&nbsp;(A) the studies, tests and preclinical and clinical trials conducted by or on behalf of or sponsored by the Company were, and if still pending are being, conducted in all material
respects in accordance with standard medical and scientific research procedures and controls, (B)&nbsp;none of the studies, tests and preclinical and clinical trials conducted by or on behalf of or sponsored by the Company involved any investigator
who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct, (C)&nbsp;the Company is not aware of any studies, tests or trials the results of which reasonably call into question the
clinical trial results described or referred to in the Pricing Prospectus and the Prospectus and (D)&nbsp;except as disclosed in the Pricing Prospectus, the Company and its subsidiaries have not received any communication, notice or correspondence
from any governmental agencies requiring the termination, material modification or suspension of any studies, tests or preclinical and clinical trials conducted by or on behalf of or sponsored by the Company; (iv)&nbsp;each description of any
studies, tests or preclinical and clinical trials conducted by or on behalf of or sponsored by the Company contained in the Pricing Prospectus is accurate and complete in all material respects and fairly presents the data about and derived from such
studies, tests and trials and (v)&nbsp;all manufacturing, packaging, processing, labeling, distribution, marketing, promotion, storage, import, export or disposal of the Company&#146;s or its subsidiaries&#146; products by the Company, its
subsidiaries or their suppliers, vendors or partners have been conducted in compliance with all applicable laws, rules and regulations; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) None of the Company&#146;s subsidiaries incorporated or formed outside of the U.S. (each, a
<FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> subsidiary&#148;) was a &#147;passive foreign investment company&#148; (&#147;PFIC&#148;) as defined in Section&nbsp;1297 of the United States Internal Revenue Code of 1986, as amended, for the
most recently completed taxable year; and the Company does not expect any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiary to be classified as a PFIC in the current taxable year (taking into account the application of the proceeds from
the offering of the Shares hereunder) or for any future taxable year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Subject to the terms and conditions herein set forth,
(a)&nbsp;the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $38.7125, the number of Firm Shares set forth
opposite the name of such Underwriter in Schedule&nbsp;I hereto and (b)&nbsp;in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each
of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per Optional
Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such
election shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such
Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to
1,200,000 Optional Shares, at the purchase price per share set forth in the paragraph above, for the sole purpose of covering sales of shares in excess of the number of Firm Shares, provided that the purchase price per Optional Share shall be
reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written
notice from you to the Company, given within a period of 30 calendar days after the date of this Agreement, setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as
determined by you but in no event earlier than the First Time of Delivery (as defined in Section&nbsp;4 hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than ten business days after the date of such
notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Upon the authorization by you of the release of the Firm Shares, the several Underwriters propose to offer the Firm Shares for
sale upon the terms and conditions set forth in the Pricing Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. (a) The Shares to be purchased by each
Underwriter hereunder, in definitive or book-entry form, and in such authorized denominations and registered in such names as the Representatives may request upon at least forty-eight hours&#146; prior notice to the Company shall be delivered by or
on behalf of the Company to the Representatives, through the facilities of the Depository Trust Company (&#147;DTC&#148;), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by
wire transfer of Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds to the accounts specified by the Company to the Representatives at least forty-eight hours in advance. The time and date of such delivery and payment shall be, with
respect to the Firm Shares, 9:30 a.m., New York City time, on August&nbsp;21, 2017 or such other time and date as the Representatives and the Company may agree upon in writing and, with respect to the Optional Shares, 9:30 am, New York time, on the
date specified by the Representatives in the written notice given by the Representatives of the Underwriters&#146; election to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in
writing. Such time and date for delivery of the Firm Shares is herein called the &#147;First Time of Delivery&#148;, each such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the &#147;Second
Time of Delivery&#148;, and each such time and date for delivery is herein called a &#147;Time of Delivery&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The documents to be
delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(q) hereof<B>
</B>will be delivered at the offices of Perkins Coie LLP, 505 Howard Street, Suite 1000, San Francisco, CA 94105 (the &#147;Closing Location&#148;), and the Shares will be delivered at the office of DTC or its designated custodian, all at such Time
of Delivery. A meeting will be held at the Closing Location at 5:30 p.m., New York City time, on the New York Business Day next preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the
preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#147;New York Business Day&#148; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking
institutions in New York City are generally authorized or obligated by law or executive order to close. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act not later than the
Commission&#146;s close of business on the second business day following the execution and delivery of this Agreement, to make no further amendment or any supplement to the Registration Statement, any Preliminary Prospectus or the Prospectus prior
to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes
effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all other material required to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to
file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and
for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Shares; to advise you, promptly after it receives notice thereof, of the
issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus in respect of the Shares, of any notice of objection of the Commission to the use of the Registration
Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such
purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; in the event of the issuance of any stop order or of any order preventing or suspending the
use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; and in the event of any such issuance of a notice of objection, promptly to take
such steps including, without limitation, amending the Registration Statement or filing a new registration statement as may be necessary to permit offers and sales of the Shares by the Underwriters (references herein to the Registration Statement
shall include any such amendment or new registration statement); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If required by Rule 430B(h) under the Act, to prepare a form of
prospectus in a form approved by you and to file such form of prospectus pursuant to Rule 424(b) under the Act not later than may be required by Rule 424(b) under the Act; and to make no further amendment or supplement to such form of prospectus
which shall be disapproved by you promptly after reasonable notice thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If by the third anniversary (the &#147;Renewal
Deadline&#148;) of the initial effective date of the Registration Statement the Underwriters notify the Company that any of them continue to hold Shares acquired hereunder that remain unsold by them, the Company will file, if it has not already done
so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to you. If at the Renewal Deadline the Company is no longer eligible to file an automatic shelf registration statement, the
Company will, if it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to you and will use its best efforts to cause such registration statement to be declared effective within 180 days
after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the public offering and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References
herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be; Promptly from time to time to take such action as you may reasonably request to qualify
the Shares for offering and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as
long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement (or such later time
as may be agreed to by the Company and the Representatives on behalf of the Underwriters) and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities as you may
reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection
with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for
any other reason it shall be necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Act or the Exchange Act, to
notify you and upon your request to file such document and to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written and electronic copies as you may from time to time reasonably request of an amended
Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under
the Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written
and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To
make generally available to its securityholders as soon as practicable, but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the
Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) During a period of 90 days from the date of the Prospectus (the &#147;Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period&#148;), the Company will not, without the prior written consent of the Representatives, on behalf of the Underwriters, (x)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration
statement under the Act with respect to any of the foregoing, (y)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common
Stock, whether any such swap or transaction described in clause (x)&nbsp;or (y) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (z)&nbsp;publicly announce an intention to effect any such swap,
agreement or other transaction described in clauses (x)&nbsp;and (y). The foregoing sentence shall not apply to (A)&nbsp;the Shares to be sold hereunder; (B)&nbsp;any shares of Common Stock issued by the Company upon the exercise of an option or
warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement, the Pricing Disclosure Package and the Prospectus; (C)&nbsp;any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of
the Company referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (D)&nbsp;any shares of Common Stock issued pursuant to any existing <FONT STYLE="white-space:nowrap">non-employee</FONT> director stock plan or
dividend reinvestment plan referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (E)&nbsp;the filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a
successor form thereto; (F)&nbsp;the issuance by the Company of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock in connection with any licensing, commercialization, joint venture,
technology transfer or development collaboration agreement relating to the Company&#146;s product candidates and commercial credit, equipment financing or commercial property lease transactions; provided that, in the case of clause (F), the
aggregate number of shares of Stock that the Company may sell or issue or agree to sell or issue shall not exceed 5% of the total number of shares of Stock issued and outstanding immediately following the Time of Delivery; provided further that, in
the case of clause (F), the Company shall cause each recipient of such securities to execute and deliver to you, on or prior to the issuance of such securities, a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with substantially the same
terms as the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referenced in Section&nbsp;8(o) of this Agreement for the remainder of the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; Notwithstanding anything contained in
any agreement referenced in Section&nbsp;8(o) of this Agreement to the contrary, Goldman Sachs&nbsp;&amp; Co. LLC herein assigns any and all rights to waive provisions contained in any agreement referenced in Section&nbsp;8(o) of this Agreement to
Goldman Sachs&nbsp;&amp; Co. LLC, Citigroup Global Markets Inc. and Leerink Partners LLC, jointly; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To furnish to its stockholders as
soon as practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries certified by independent public
accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders
consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail; provided that no reports, documents or other information need to be furnished pursuant to this Section&nbsp;5(g) to the extent they
are available on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) During a period
of five years from the effective date of the Registration Statement, to furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to you (i)&nbsp;as soon as they are available, copies
of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed and (ii)&nbsp;such additional information concerning the business and
financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its subsidiaries are consolidated in reports furnished to its
stockholders generally or to the Commission); provided that no reports, documents or other information need to be furnished pursuant to this Section&nbsp;5(h) to the extent they are available on EDGAR; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner specified in the Pricing
Prospectus under the caption &#147;Use of Proceeds&#148;; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) To use its best efforts to list for trading, subject to official notice of
issuance, the Shares on The NASDAQ Stock Market (the &#147;Exchange&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) To file with the Commission such information on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K</FONT> as may be required by Rule 463 under the Act; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Upon request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&#146;s
trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the <FONT STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#147;License&#148;); provided,
however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. (a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer
relating to the Shares that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 under the Act and each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not
made and will not make any offer relating to the Shares that would constitute a free writing prospectus; any such free writing prospectus the use of which has been consented to by the Company and the Representatives is listed on Schedule II(a)
hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing
Prospectus, including timely filing with the Commission or retention where required and legending; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that if at
any time following issuance of an Issuer Free Writing Prospectus any event occurred or occurs as a result of which such Issuer Free Writing Prospectus would conflict with the information in the Registration Statement, the Pricing Prospectus or the
Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt
notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus or other document which will correct such conflict, statement or omission;
provided, however, that this covenant shall not apply to any statements or omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including
(i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies
of each Issuer Free Writing Prospectus, any Preliminary Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors,
(iii)&nbsp;the preparation, issuance and delivery of the certificates for the Shares to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Shares to the
Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Shares under securities laws in accordance with the provisions of the final clause of
Section&nbsp;5(c) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a &#147;Blue Sky Survey&#148; and any supplement thereto up
to a maximum of $2,500, (vi) the fees and expenses of any transfer agent or registrar for the Shares, (vii)&nbsp;the filing fees incident to, and up to a maximum of $30,000 of the reasonable fees and disbursements of counsel to the Underwriters in
connection with, the review by FINRA of the terms of the sale of the Shares, (viii)&nbsp;the fees and expenses incurred in connection with the listing of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares on the Nasdaq Global Select Market, and (ix)&nbsp;the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual
liability) associated with the reforming of any contracts for sale of the Shares made by the Underwriters caused by a breach of the representation contained in Section&nbsp;1(b). It is understood, however, that except as provided in this
Section&nbsp;7, and Sections 9 and 12 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and any advertising expenses connected
with any offers they may make. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each Time of
Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition
that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Prospectus shall have been filed with the Commission pursuant to Rule&nbsp;424(b) under the Act within the applicable time period
prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission
within the applicable time period prescribed for such filing by Rule 433; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been
initiated or threatened by the Commission and no notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act shall have been received; no stop order
suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall
have been complied with to your reasonable satisfaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Perkins Coie LLP, counsel for the Underwriters, shall have furnished to you
such written opinion or opinions, dated the Time of Delivery, in form and substance satisfactory to the Representatives, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such papers and
information as they may reasonably request to enable them to pass upon such matters; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Cooley LLP, counsel for the Company, shall have
furnished to you their written opinion, dated the Time of Delivery, in form and substance satisfactory to you; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Leanne Price,
intellectual property counsel for the Company, shall have furnished to the Underwriters her written opinion, dated the Time of Delivery, in form and substance satisfactory to you; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) DeHeng Law Offices, PRC counsel for the Company, shall have furnished to the Company their written opinion, dated the Time of Delivery, in
form and substance satisfactory to you; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) DLA Piper Hong Kong, Hong Kong counsel for the Company, shall have furnished to the
Underwriters their written opinion, dated the Time of Delivery, in form and substance satisfactory to you; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Ogier LLP, Cayman Islands
counsel for the Company, shall have furnished to the Underwriters their written opinion, dated the Time of Delivery, in form and substance satisfactory to you; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Appleby (Cayman) Ltd., Cayman Islands counsel for the Company, shall have furnished to the
Underwriters their written opinion, dated the Time of Delivery, in form and substance satisfactory to you; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) White&nbsp;&amp; Case LLP,
Finnish counsel for the Company, shall have furnished to the Underwriters their written opinion, dated each Time of Delivery, in form and substance satisfactory to you; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) On the date of the Prospectus at a time immediately following the execution of this Agreement, at 9:30 a.m., New York City time, on the
effective date of any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at the Time of Delivery, PricewaterhouseCoopers LLP, who have audited the
financial statements of the Company and its subsidiaries included or incorporated by reference in the Registration Statement and who have audited the effectiveness of the Company&#146;s internal control over financial reporting and management&#146;s
assessment thereof, shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to you; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included
or incorporated by reference in the Pricing Prospectus and the Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus and the Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Prospectus and the Prospectus
there shall not have been any change in the capital stock or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting the
general affairs, management, financial position, stockholders&#146; equity or results of operations of the Company and its subsidiaries, otherwise than as set forth or contemplated in the Pricing Prospectus and the Prospectus, the effect of which,
in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery
on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) On or after the Applicable Time (i)&nbsp;no
downgrading shall have occurred in the rating accorded the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization&#148;, as defined in Section&nbsp;3(a)(62) of the Exchange Act and (ii)&nbsp;no such
organization shall have publicly announced that it has under surveillance or review, with possible negative implications, its rating of any of the Company&#146;s debt securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) On or after the Applicable Time there shall not have occurred any of the following: (i)&nbsp;a suspension or material limitation in trading
in securities generally on the Exchange; (ii)&nbsp;a suspension or material limitation in trading in the Company&#146;s securities on the Exchange;<B> </B>(iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or
New York or California<B> </B>State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv)&nbsp;the outbreak or escalation of hostilities involving the United States or
the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such
event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated
in the Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Shares to be sold at such Time of Delivery shall have been duly listed, subject to
official notice of issuance, on the Exchange; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company shall have obtained and delivered to the Underwriters executed copies of an
agreement from (i)&nbsp;each holder named in a list of holders of the Company&#146;s securities satisfactory to you, (ii)&nbsp;each member of the Company&#146;s board of directors, (iii)&nbsp;each officer of the Company and (iv)&nbsp;certain other
holders of the Company&#146;s securities as you may request, substantially to the effect set forth in Annex I hereto in form and substance satisfactory to you; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Company shall have complied with the provisions of Section&nbsp;5(d) hereof with respect to the furnishing of prospectuses on the New
York Business Day next succeeding the date of this Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The Company shall have furnished or caused to be furnished to you at
such Time of Delivery certificates of officers of the Company, satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its
obligations hereunder to be performed at or prior to such Time of Delivery, and as to such other matters as you may reasonably request, and the Company shall have furnished or caused to be furnished certificates as to the matters set forth in
subsections (a)&nbsp;and (k) of this Section&nbsp;8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. (a) The Company will indemnify and hold harmless each Underwriter against any
losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon
an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing
Prospectus or any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Act, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as such
expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission
or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, in reliance upon and in conformity with the
Underwriter Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter will severally and not jointly indemnify and hold harmless the Company against any losses,
claims, damages or liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, or arise out of or are
based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or
alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, in
reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document,
&#147;Underwriter Information&#148; shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished
by any Underwriter consists of the following information in the Basic Prospectus, the Pricing Prospectus, any Preliminary Prospectus or the Prospectus furnished on behalf of each Underwriter: the information contained under the caption
&#147;Underwriting&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b) of this Section&nbsp;9 of
notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the
omission so to notify the indemnifying party shall not relieve it from any liability which it may have to any indemnified party otherwise than under such subsection. In case any such action shall be brought against any indemnified party and it shall
notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party
of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such
indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the
entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or
claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of
fault, culpability or a failure to act, by or on behalf of any indemnified party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this
Section&nbsp;9 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a)&nbsp;or (b) of this Section&nbsp;9 in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to
therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect
the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law or if the
indemnified party failed to give the notice required under subsection (c)&nbsp;above, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only
such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect
thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the
offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall
be determined by reference to, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one
hand or the Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to this subsection (d)&nbsp;were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection
(d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), no
Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such
Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this subsection (d)&nbsp;to contribute are several in proportion to their respective underwriting obligations and
not joint. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company under this Section&nbsp;9 shall be in addition to any liability which the Company may
otherwise have and shall extend, upon the same terms and conditions, to each officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act, each broker-dealer affiliate of any
Underwriter and each selling agent of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms
and conditions, to each officer and director of the Company and to each person, if any, who controls the Company within the meaning of the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. (a) If any Underwriter shall default in its obligation to purchase the Shares that it has agreed to purchase hereunder at a Time of
Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter
you do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party or other parties satisfactory to you to
purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the Company that you have so arranged for the purchase of such Shares, or the Company notifies you that it has so arranged for the purchase
of such Shares, you or the Company shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or
in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#147;Underwriter&#148; as
used in this Agreement shall include any person substituted under this Section&nbsp;10 with like effect as if such person had originally been a party to this Agreement with respect to such Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by you and the Company as provided in subsection (a)&nbsp;of this Section&nbsp;10, the aggregate number of such Shares which remains unpurchased does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the
aggregate number of all the Shares to be purchased at such Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Shares which such
Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the number of Shares which such
Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;of this Section&nbsp;10, the aggregate number of such Shares which remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all of the Shares to be
purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;of this Section&nbsp;10 to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Shares of a
defaulting Underwriter or Underwriters, then this Agreement or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares, shall thereupon terminate, without liability
on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7 hereof and the indemnity and contribution
agreements in Section&nbsp;9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The
respective indemnities, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain
in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any controlling person of any Underwriter, or the Company, or any officer or director or controlling
person of the Company, and shall survive delivery of and payment for the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. If this Agreement shall be terminated pursuant to
Section&nbsp;10 hereof, the Company shall not then be under any liability to any Underwriter except as provided in Sections 7 and 9 hereof; but, if for any other reason any Shares are not delivered by or on behalf of the Company as provided herein,
the Company will reimburse the Underwriters through you for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including fees and disbursements of counsel,
reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to
act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs&nbsp;&amp; Co. LLC on behalf of you as the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into
law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as
well as other information that will allow the Underwriters to properly identify their respective clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and if to the
Underwriters shall be delivered or sent by mail, telex or facsimile in care of Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department; Citigroup Global Markets Inc., 388 Greenwich Street,
New York, New York 10013 Attention: General Counsel, facsimile number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-646-291-1469;</FONT></FONT></FONT> Leerink Partners LLC, One Federal Street,
37F, Boston, MA 02110, Facsimile: (617) <FONT STYLE="white-space:nowrap">918-4664,</FONT> Attention: John I. Fitzgerald; if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth on
the cover of the Registration Statement, Attention: Michael Lowenstein, Vice President, Legal Affairs; and if to any stockholder that has delivered a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;8(o) hereof shall
be delivered or sent by mail to his or her respective address as such stockholder provides in writing to the Company; provided, however, that any notice to an Underwriter pursuant to Section&nbsp;9(c) hereof shall be delivered or sent by mail, telex
or facsimile transmission to such Underwriter at its address set forth in its Underwriters&#146; Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the Company by you upon request. <B></B>Any such statements,
requests, notices or agreements shall take effect upon receipt thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. This Agreement shall be binding upon, and inure solely to the
benefit of, the Underwriters and the Company and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, and their respective heirs, executors,
administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such
purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Time shall be of the essence of this Agreement. As used herein, the term &#147;business day&#148; shall mean any day when
the Commission&#146;s office in Washington, D.C. is open for business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. The Company acknowledges and agrees that (a)&nbsp;the purchase
and sale of the Shares pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other; (b)&nbsp;in connection
therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company; (c)&nbsp;no Underwriter has assumed an advisory or fiduciary responsibility in favor of the
Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other obligation to the Company except the
obligations expressly set forth in this Agreement and (d)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed appropriate. The Company agrees that it will not claim that the Underwriters, or any of them, has
rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or
any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18. THIS AGREEMENT AND ANY MATTERS RELATED TO THIS TRANSACTION SHALL BE
GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAWS OF THE STATE OF NEW YORK. The Company agrees that any
suit or proceeding arising in respect of this agreement or our engagement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court
located in The City and County of New&nbsp;York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be
an original, but all such counterparts shall together constitute one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. Notwithstanding anything herein to the
contrary, the Company is authorized to disclose to any persons the U.S. Federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to
the Company relating to that treatment and structure, without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall
not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, &#147;tax structure&#148; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance of this letter by signing in the space provided
below, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement among each of the Underwriters and the Company. It is understood that your acceptance of
this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination, upon request, but without warranty on your part
as to the authority of the signers thereof. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FibroGen, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Pat Cotroneo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Pat Cotroneo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Accepted as of the date hereof:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>GOLDMAN SACHS&nbsp;&amp; CO. LLC</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Cohn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Richard Cohn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>CITIGROUP GLOBAL MARKETS INC.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Chung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Chung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>LEERINK PARTNERS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John I. Fitzgerald, Esq.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John I. Fitzgerald, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>On behalf of each of the Underwriters<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number&nbsp;of<BR>Firm Shares</B><br><B>to be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Optional&nbsp;Shares<BR>to be Purchased<BR>if Maximum<BR>Option<BR>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co LLC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Issuer Free Writing Prospectuses </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Documents filed with the Commission since the close of business on the business day immediately prior to the date of the execution of this Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX I </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">August [X], 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets
Inc., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives (the
&#147;Representatives&#148;) of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">named in Schedule I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Federal St, 37F </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Proposed Public Offering by FibroGen, Inc.</U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, an officer and/or director of FibroGen, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), understands that
Goldman Sachs&nbsp;&amp; Co. LLC, Citigroup Global Markets Inc. and Leerink Partners LLC propose to enter into an Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) with the Company providing for the public offering (the
&#147;<U>Public Offering</U>&#148;) of shares (the &#147;<U>Securities</U>&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;<U>Common Stock</U>&#148;). In recognition of the benefit that such an offering will confer
upon the undersigned as an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the
Underwriting Agreement (collectively, the &#147;<U>Underwriters</U>&#148;) that, during the period beginning on the date hereof and ending on the date that is 60 days from the date of the Underwriting Agreement (the &#147;<U><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;), the undersigned will not, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC on behalf of the Underwriters, directly or indirectly, (i)&nbsp;offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of
disposition (collectively, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities</U>&#148;), or exercise any right with respect to the registration of any of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or file
or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, provided, in each case, that (1)&nbsp;Goldman Sachs&nbsp;&amp; Co. LLC receives a signed
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, trustee, distributee, or transferee, as the case may be, (2)&nbsp;any such transfer shall not
involve a disposition for value, (3)&nbsp;such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the
&#147;<U>Exchange Act</U>&#148;), and (4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">as a <I>bona fide</I> gift or gifts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#147;immediate family&#148;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members or retired members or by a corporation to its stockholders or former stockholders
or to any wholly-owned subsidiary of such corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a qualified domestic relations order or in connection with a divorce settlement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">by will or intestate succession upon the death of the undersigned; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">to the Company in satisfaction of any tax withholding obligation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, no provision
in this letter shall be deemed to restrict or prohibit (1)&nbsp;the transfer of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to the Company in connection with the termination of the undersigned&#146;s services to
the Company, provided that any filing under Section&nbsp;16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (1); (2) the
exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case for cash or on a &#147;cashless&#148; or &#147;net exercise&#148; basis, pursuant to
any stock option, stock bonus or other stock plan or arrangement; provided, however, that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter and that any filing under
Section&nbsp;16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate in the footnotes thereto that (a)&nbsp;the filing relates to the circumstances described in this clause (2)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (b)&nbsp;no shares were sold by the reporting person; (3)&nbsp;the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities upon the completion of a bona fide third-party tender
offer, merger, consolidation or other similar transaction made to all holders of the Company&#146;s securities involving a change of control (defined as a change in the ownership of more than 65% of the voting capital stock of the Company in one or
more related transactions) of the Company; provided, however, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the
restrictions on transfer set forth in this letter; and (4)&nbsp;the conversion of outstanding preferred stock of the Company into shares of Common Stock, provided that any such shares received upon such conversion shall be subject to the
restrictions on transfer set forth in this letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, nothing herein shall prevent the
undersigned from establishing a <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act <FONT STYLE="white-space:nowrap">(&#147;10b5-1</FONT> Trading
Plan&#148;) or from amending an existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan so long as there are no sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities under any such
<FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; and provided that, the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan or the amendment of
a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan shall only be permitted if (i)&nbsp;the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission, or
otherwise and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan. Additionally, the foregoing restrictions shall not apply to transfers of shares of
Common Stock made pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan that has been entered into prior to the date of this agreement, provided that if the undersigned reports any such transfer on a Form 4 filed with the
Securities and Exchange Commission pursuant to Section&nbsp;16 of the Exchange Act, the undersigned shall cause such Form 4 to include a statement that such transfer was effected pursuant to a trading plan meeting the requirements of Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer
instructions with the Company&#146;s transfer agent and registrar against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. This
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement shall automatically terminate, and the undersigned shall be released from the undersigned&#146;s obligations hereunder, upon the earliest to occur, if any, of (i)&nbsp;prior to the execution
of the Underwriting Agreement, the Company advises Goldman Sachs&nbsp;&amp; Co. LLC in writing that it has determined not to proceed with the Public Offering; (ii)&nbsp;the Underwriting Agreement is executed but is terminated prior to the closing of
the Public Offering (other than the provisions thereof which survive termination), or (iii)&nbsp;September&nbsp;30, 2017, in the event that the Underwriting Agreement has not been executed by such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OWNERSHIP STRUCTURE </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Organizational Chart </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">And its Cayman, Hong Kong and China Subsidiaries </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g440461dsp33.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d440461dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g440461g0816061805414.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael E. Tenta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 650 843
5636 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mtenta@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;15, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">409 Illinois Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94158 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: FibroGen, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to FibroGen,
Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the offering of 8,000,000 shares of the Company&#146;s common stock, $0.01 par value (the &#147;<B><I>Shares</I></B>&#148;), pursuant the Registration Statement
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under the Securities Act of 1933, as amended (the
&#147;<B><I>Act</I></B>&#148;), the prospectus included in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;), and the prospectus supplement relating to the Shares filed with the Commission pursuant to Rule 424(b) promulgated
under the Act (the &#147;<B><I>Prospectus Supplement</I></B>&#148; and, together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). The Company has requested our opinion in connection with certain related matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon (a)&nbsp;the Registration Statement and the Prospectus, (b)&nbsp;the Company&#146;s Amended
and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, and (c)&nbsp;originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other
instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all
documents submitted to us as copies thereof; the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents where due execution and delivery are a prerequisite to
the effectiveness thereof (except we have not assumed the due authorization, execution and delivery by the Company of any such documents). As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not
sought independently to verify such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We
express no opinion to the extent that of any other laws are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or state law, rule or regulation relating to securities, or to the sale or
issuance thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with
the Registration Statement and the Prospectus, will be validly issued, fully paid, and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (650) <FONT
STYLE="white-space:nowrap">843-5000</FONT> f: (650) <FONT STYLE="white-space:nowrap">849-7400</FONT> cooley.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g440461g0816061805414.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;15, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page
Two </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to the filing of this opinion as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed with the Commission for incorporation by reference into the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>OOLEY</SMALL> LLP </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael E. Tenta</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael E. Tenta</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto,
CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (650) <FONT STYLE="white-space:nowrap">843-5000</FONT> f: (650)
<FONT STYLE="white-space:nowrap">849-7400</FONT> cooley.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d440461dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">


<IMG SRC="g440461g36p55.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">NEWS RELEASE</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIBROGEN, INC. ANNOUNCES PRICING OF <FONT STYLE="white-space:nowrap">FOLLOW-ON</FONT> OFFERING OF COMMON
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, Aug. 15, 2017 &#151; FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it has priced
an underwritten <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, which is expected to raise gross proceeds of approximately $326&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen is offering 8,000,000 shares of its common stock at an offering price of $40.75 per share, before underwriting discounts and commissions. All of the
shares are being offered by FibroGen. In addition, FibroGen has also granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 1,200,000 shares of common stock. The offering is expected to close
on August&nbsp;21, 2017, subject to customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC, Citigroup and Leerink Partners LLC are acting as
joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These securities are registered pursuant to an automatic shelf
registration statement filed with the U.S. Securities and Exchange Commission on March&nbsp;1, 2017 and the offering is being made only by means of a written prospectus forming part of the effective registration statement. A preliminary prospectus
related to the offering has been filed with the SEC and is available on the SEC&#146;s website, located at www.sec.gov. A copy of the final prospectus relating to these securities, when available, may be obtained from Goldman Sachs&nbsp;&amp; Co.
LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) <FONT STYLE="white-space:nowrap">471-2526,</FONT> facsimile: (212) <FONT STYLE="white-space:nowrap">902-9316</FONT> or by emailing <FONT
STYLE="white-space:nowrap">prospectus-ny@ny.email.gs.com;</FONT> Citigroup, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) <FONT STYLE="white-space:nowrap">831-9146;</FONT> or Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) <FONT STYLE="white-space:nowrap">808-7525,</FONT> ext. 6132 or by email to syndicate@leerink.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in
San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance
innovative medicines for the treatment of anemia, fibrotic disease, and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of
anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective
tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. FibroGen is currently conducting clinical studies of
pamrevlumab in pancreatic cancer and Duchenne muscular dystrophy (DMD), and recently completed a Phase 2 double-blind study in idiopathic pulmonary fibrosis (IPF). In desmoplastic or fibrotic cancers, such as pancreatic cancer, CTGF promotes
abnormal proliferation of stromal and tumor cells. FibroGen is also developing a biosynthetic cornea in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes forward-looking statements, including with respect to the anticipated closing of the offering described herein, intended to qualify
for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are
not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent
management&#146;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are
not limited to, the risks discussed in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> filed with the SEC on March&nbsp;1, 2017, as updated by the risks reported in our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We
caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than
as required under the Federal securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (415) <FONT
STYLE="white-space:nowrap">978-1433</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kbergman@fibrogen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g440461dsp33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g440461dsp33.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P"@%HW_ (-Y?_D:@ ^V>,/^@%HW_@WE_P#D:@ ^V>,/^@%HW_@WE_\ D:@
M^V>,/^@%HW_@WE_^1J #[9XP_P"@%HW_ (-Y?_D:@ ^V>,/^@%HW_@WE_P#D
M:@ ^V>,/^@%HW_@WE_\ D:@ ^V>,/^@%HW_@WE_^1J #[9XP_P"@%HW_ (-Y
M?_D:@ ^V>,/^@%HW_@WE_P#D:@ ^V>,/^@%HW_@WE_\ D:@ ^V>,/^@%HW_@
MWE_^1J #[9XP_P"@%HW_ (-Y?_D:@ ^V>,/^@%HW_@WE_P#D:@ ^V>,/^@%H
MW_@WE_\ D:@ ^V>,/^@%HW_@WE_^1J #[9XP_P"@%HW_ (-Y?_D:@ ^V>,/^
M@%HW_@WE_P#D:@ ^V>,/^@%HW_@WE_\ D:@ ^V>,/^@%HW_@WE_^1J #[9XP
M_P"@%HW_ (-Y?_D:@ ^V>,/^@%HW_@WE_P#D:@ ^V>,/^@%HW_@WE_\ D:@
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M&\H)8B$.DO\ *YC%MT:C>\?Z_4V?$VM^)O"4<-M)J4=V^L:Q%:64[Q+NMH7
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M<T =!0 4 <_X$_Y)YX:_[!=M_P"BEH Z"@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M-_X-Y?\ Y&H /MGC#_H!:-_X-Y?_ )&H /MGC#_H!:-_X-Y?_D:@ ^V>,/\
MH!:-_P"#>7_Y&H /MGC#_H!:-_X-Y?\ Y&H /MGC#_H!:-_X-Y?_ )&H /MG
MC#_H!:-_X-Y?_D:@ ^V>,/\ H!:-_P"#>7_Y&H /MGC#_H!:-_X-Y?\ Y&H
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M^#>7_P"1J #[9XP_Z 6C?^#>7_Y&H /MGC#_ * 6C?\ @WE_^1J #[9XP_Z
M6C?^#>7_ .1J #[9XP_Z 6C?^#>7_P"1J #[9XP_Z 6C?^#>7_Y&H /MGC#_
M * 6C?\ @WE_^1J *[VOB34]:T6:_P!/TRTM;"Z:X=H+^29VS!+& %,*#K(#
MG/:@#J* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Y^\_P"2AZ-_V"[[_P!&VM '04 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % '/WG_)0]&_[!=]_Z-M: .@H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#G[S_DH>C?]@N^_]&VM '04 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/WG_ "4/1O\ L%WW
M_HVUH Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H Y^\_Y*'HW_8+OO\ T;:T =!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 C,L:,['"J,D^@H YN2ZM[OQOH-W;S)+;2Z1>R)*
MC95E,EH00?3% '06MU!>VL5U:S)-;S('CD0Y5U(R"#W% $M !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F6H>'=87QQ9Z/9Q,N@S
MVUUNN0QS!%))"\D(]R4(7IA9#C[E 'I<<:0Q)%&H1$ 5548  Z"@!U !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % ''V>CPZWX@\2O>WFI_Z/?I#$D&IW$"(GV6!
ML!8W4?>=CT[T :'_  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0
M ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:
MS_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM !_P
MANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N
M\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  AN
ME_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_
M^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/U
MK/\ X.[S_P".T 2>"YYKKP+X>N+B5YIY=.MWDDD8LSL8U)))Y))[T ;E !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVO\ ,B3O!6Z3M^$OPT3/1:DHY_P)_P D\\-?]@NV_P#12T =!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!S_A[_D.>+/^PHG_ *1VU %[6] T[Q#:1VNIQ22PQRK,JI.\6'7E3E""<'GZ
MT+22DMT'1QZ,+S0-.O\ 5;'4[F%WO+ ,+=Q,ZA-PPWR@X.1Z@T;-ONK?(-TH
M]M3(E\)>$]+M)%N(EMK>XB^QCSKR155'(!C3+_)N.,[<$GKFA^\N3O\ IM\E
MVV'=I\_:[^_=^OF:,WA;1Y]*LM->VD%O8X^S%+B19(<# VR!@XXXZ].*<FY2
MYGN3%*,>5;#;CPEH=S:V=NUCY260*V[02O"\8/4!D(;![C//>D]7=^GR[>GD
M/I;Y_/OZ^8S_ (0[0A%811V30K8*4MS#/)&50G)0E6!93W4Y'M3N[W^7W;"M
M96\[_-D=_P"!] U.>]FNK69GO1&L^V[F0.(^4&%< 8]L4E[NJ[W^??\ K]!O
M7[K?+L7=1\/:;JMWI]U>12O-I\GF6S+<2)L;&,D*P#<<<YZGU--.TN9;[!:\
M>3H9:^%/"NC75A.VZWECNI)+7SM0EP9I =V%9\,2,\<]^.31'2T5VM\@E[UY
M/O=^O0L_\(7H L8K-+.2.&&4S0F.YE1X6.<['#!D')X4@<D8I)VM;II\OUV6
MX/6]^NI:A\.:7;ZTNKQ6[K?+;_9@_G/CR\YV[<[>O.<9H6ETNN_R$U>U^GZE
M&#P)X>MY8)([2?=!-)/&&O)F >08<X+X.>>#ZGU-'3EZ6M\NQ3=W?SO\Q;;P
M-X=M(WCBL&*26GV)UDN)7#0Y)"'<QR!DX[@<# IR;E=/K;[UL_7S$M&FNE_Q
MW^7EL21>#-!BNC<_8GDE-H;)O.N)) T)Y*LK,0WU(S[T-WYK]=P6EK=-OZ_K
MIV*=YX7\)6FG?V5?;8H;^2.,">_D$DS*<HBN7WG'90<#TH3;DDMUK\^_GZL6
MD4WTV^7;R]"U_P (3H/GRS_9IS-+<K=-(;R8MYJJ5# [^/E.,#@C@TEHDO7\
M=QO6_HE]VW_#[BV?@O0;"XL)[6TEB?3S(;8+=2[8]YRXV[L$'/0C%--K5=K?
M) U??O?Y_P!?KW-^D!S_ ($_Y)YX:_[!=M_Z*6@#H* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .?\/?\
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MKJK_ '?IJ>PU)04 % '/^!/^2>>&O^P7;?\ HI: .@H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% &/?>$_#>IWDEY?^'],N[J3&^:>SC=VP,#+$9/  _"@"O\ \()X/_Z%31O_
M   B_P#B: #_ (03P?\ ]"IHW_@!%_\ $T '_"">#_\ H5-&_P# "+_XF@ _
MX03P?_T*FC?^ $7_ ,30 ?\ "">#_P#H5-&_\ (O_B: #_A!/!__ $*FC?\
M@!%_\30 ?\()X/\ ^A4T;_P B_\ B: #_A!/!_\ T*FC?^ $7_Q- '/W/@SP
MLOQ#TRU'AK21;OI=U(T0LH]K,);<!B,8R S 'W/K0!T'_"">#_\ H5-&_P#
M"+_XF@ _X03P?_T*FC?^ $7_ ,30 ?\ "">#_P#H5-&_\ (O_B: #_A!/!__
M $*FC?\ @!%_\30 ?\()X/\ ^A4T;_P B_\ B: #_A!/!_\ T*FC?^ $7_Q-
M !_P@G@__H5-&_\  "+_ .)H /\ A!/!_P#T*FC?^ $7_P 30 ?\()X/_P"A
M4T;_ , (O_B: -R""&UMXK>WB2&")0D<<:A510,  #@ #M0!)0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!S5U_R4W2O^P1>?^CK:@#I: "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#FKK_ )*;I7_8(O/_ $=;
M4 =+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M<U=?\E-TK_L$7G_HZVH Z6@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@!&#%&"MM;'!QG!H \SE\42V_BJPDO80^LVNFW=G);1C'F
MW!FM@FT<D*^58>BGGH: /1K);E+&W6]D26Z$:B5XUVJSXY(&3@9[9H GH *
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M[9XP_P"@%HW_ (-Y?_D:@ ^V>,/^@%HW_@WE_P#D:@ ^V>,/^@%HW_@WE_\
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MN4;*+[I/[R;^])=F='4#"@ H * "@#G_  )_R3SPU_V"[;_T4M '04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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ME<12S0FP)<*@"[%?S,#(&"=IZ\8I4_=CRO57;^\<_>ES+>R7W?\ #E9/ ,T
M@,&KA6M-4?4;;=;9"[RV]'&X;OOG!&W''!YRXOEY?)<OR_S"?O<WFT_FK?AY
M%_PUX8U#P]%#;?VTL]JD]Q-)&+4(9/,;<,G<<;26Z8SGIQ0G[J3Z)+[NOW ]
M9.7=W_#;]3IZ0!0 4 % !0!S_@3_ ))YX:_[!=M_Z*6@#H* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#G_ !E_
MR [;_L*:?_Z60T =!0!'/)Y5O))_<4M^0J*DN6#:Z%17-)(X32[S4;FQ\-V<
M6JW,%UK<#7US=Y$CKA$.R-9-R(,N.-N, \9.:WG#EJ2IK:*^;UMK_79;$J5X
M^T[NWHM7^AHW_B2X\,W.E:7?2P7TMQ+'";B:XC@FE+OM!2%1\VW(W?='<9Y
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M $4M '04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:0PH * "@ H * "@ H * .?\"?\ )//#7_8+MO\ T4M '04 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/^,O\
MD!VW_84T_P#]+(: .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * .?\  G_)//#7_8+MO_12T =!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/_Z&O1O_  /B_P#BJ #_ (3OP?\ ]#7HW_@?%_\ %4 '_"=^#_\ H:]&_P#
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H P?&%R;7P^) N[-[:1XS_>N8US^M &]0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <OXNO;6XTB.&*5)7BUC3
MX954@[&^U0MAO3@@_B* .BANK>XEGCAGCD>W?9*JL"8VP&P?0X(./0B@":@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#@_'>E:I'
M<VVHZ)9_;'N+BV6>W+E5WQRJ\4I/8 @AN,D$?W: .MT;3%TG3([42-++DO-,
MWWI9&.68_4D_3IVH OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 </X;\)^&]3
MT^\O+_P_IEW=2:I?[YI[.-W;%W*!EB,G@ ?A0!L?\()X/_Z%31O_   B_P#B
M: #_ (03P?\ ]"IHW_@!%_\ $T '_"">#_\ H5-&_P# "+_XF@ _X03P?_T*
MFC?^ $7_ ,30 ?\ "">#_P#H5-&_\ (O_B: #_A!/!__ $*FC?\ @!%_\30
M?\()X/\ ^A4T;_P B_\ B: #_A!/!_\ T*FC?^ $7_Q- !_P@G@__H5-&_\
M "+_ .)H /\ A!/!_P#T*FC?^ $7_P 30 ?\()X/_P"A4T;_ , (O_B: #_A
M!/!__0J:-_X 1?\ Q- !_P ()X/_ .A4T;_P B_^)H /^$$\'_\ 0J:-_P"
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MF7RU5EW_ ,_D*A=U(N7;[][OMV5E>WS.E\;)<R> -%1+2[N9A<V4CI!;R3.
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % '/^!/^2>>&O\ L%VW_HI: .@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H Y_P &_P#(#N?^PIJ'_I9-0!T% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 <_X$_Y)YX:_[!=M_P"BEH Z"@ H * "@ H * "@ H * "@ H *
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M!\7_ ,50 ?\ "=^#_P#H:]&_\#XO_BJ #P)_R3SPU_V"[;_T4M '04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 8?B[_D6Y_^ND/_ *-2@#<H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,/Q=_R+<__72'_P!&
MI0!N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M&'XN_P"1;G_ZZ0_^C4H W* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#F/$^I6\^G:EIRDK<VKVSNC#&4:1=K#U&0P^JF@#;LM
M3M[^YO8;?>?L<ODR.5PI?:"0#WQD ^_'4&@"Y0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#G[S_DH>C?\ 8+OO_1MK0!T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#8[]:J[T\B;+5=S4I#"@ H Y^\_Y*'HW_8+OO_1MK0!T% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!S_B'_D.>$_\ L*/_ .D=S0!T% !0 4 % !0
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MK_2/$'A;3](FDWI]M>>]DL))X4:7DY"D!<DG&6XXZTDN:3CLN1+[FNO?3_@
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MIZ)>=_PM_F4-=U.^MX=3ALH8MUO9&?S7E*E2=^,#:<XVYJ7>S-(13E%/J_\
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ME^7^9-[MV[O[KC;_ %IH;N^6+5&58;;SD7R0?FRW'3I\M1>T6^QJHIRBN_\
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MRIMN";[$]06% '/WG_)0]&_[!=]_Z-M: .@H * "@ H * "@ H * "@ H *
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M984 % !0 4 % !0 4 % !0 4 % !0!S]Y_R4/1O^P7??^C;6@#H* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#G_$/_ "'/"?\ V%'_ /2.YH Z"@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H Y^\_Y*'HW_8+OO_1MK0!T% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!S_B'_D.>$_\ L*/_ .D=S0!T% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S]Y_R4/1O
M^P7??^C;6@#H* "@ H * "@ H * "@ H * "@ H * "@ H * "@#G_$/_(<\
M)_\ 84?_ -([F@#H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#G[S_DH>C?]@N^_P#1MK0!T% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!3U+2=-UBW6WU33[6^@5MZQW,*R*
M&P1D!@1G!//O0!E_\()X/_Z%31O_   B_P#B: #_ (03P?\ ]"IHW_@!%_\
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A[+L:2VM4C8KD'&5 .,@<>U &I0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g440461g0816061805414.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g440461g0816061805414.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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M/3[@?:/E<MR[+Z #@#U.>E2JD.3E_ ZY8#%RQWMT_=O?FOI;_AB_\/=6N(/
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%J>6?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g440461g36p55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g440461g36p55.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8G&?5Y*-KG.?\+K;_H C_P "?_L:ZO[+_O?A_P $YO[3_N_C_P  /^%UM_T
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MV:,QI(B11^0&8DJIQ[\FN[#X2C.BIS.+$8NM"LX0(#XI^)P&3IMS@?\ 4/\
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..K9>IS<HNQZ;7E'J'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
